Taroeno-Hariadi, Kartika Widayati and Putra, Yasjudan Rastrama and Choridah, Lina and Widodo, Irianiwati and Hardianti, Mardiah Suci and Aryandono, Teguh (2021) Fatty liver in hormone receptor-positive breast cancer and its impact on patients survival. Journal of Breast Cancer, 24 (5). 417 – 427. ISSN 17386756
Full text not available from this repository. (Request a copy)Abstract
Purpose: Long-term estrogen inhibition may cause fatty liver disease (non-alcoholic fatty liver disease; NAFLD) among other adverse conditions such as osteoporosis, climacteric symptoms, thromboembolism, dyslipidemia, and metabolic syndrome. The prevalence of NAFLD among breast cancer patients ranges from 2.3–45.2. This study aimed to determine the risk factors for newly developed NAFLD among breast cancer patients after hormonal treatment and whether it influences survival outcomes. Methods: This retrospective study investigated hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (HR+/HER2−), nonmetastatic breast cancer patients diagnosed between January 2010 and December 2018. All patients received adjuvant hormonal treatment for at least 6 months. Clinical data on metabolic profile indicators such as body mass index (BMI), waist circumference, serum cholesterol, triglycerides, low-density lipoprotein-cholesterol (LDL-C), high-density lipoprotein-cholesterol (HDL-C), diabetes, and presence of metabolic syndrome (MetS) were collected. In total, 160 eligible patients with complete covariate data and survival follow-up were included. Results: NAFLD was diagnosed in 35 of patients. There were significant associations of being overweight (BMI ≥ 25 kg/m2), waist circumference > 80 cm, triglycerides ≥ 150 mg/ dL, HDL-C ≤ 50 mg/dL, LDL-C < 150 mg/dL, and presence of MetS with the development of NAFLD. However, unlike other factors, MetS and HDL-C were not independently associated with NAFLD. Patients with breast cancer who developed NAFLD had longer disease-free survival (DFS). The median DFS was not reached in the NAFLD group, whereas it was 59.3 (45.6–73.0) months in the non-NAFLD group. No worsening of overall survival was observed in patients with breast cancer and NAFLD. Conclusion: The development of NAFLD during treatment in patients with HR+/HER2− breast cancer was associated with several independent risk factors: being overweight, waist circumference, triglycerides, and LDL-C. Interestingly, breast cancer patients with NAFLD during treatment had longer DFS than those without NAFLD. © 2021 Korean Breast Cancer Society.
Item Type: | Article |
---|---|
Additional Information: | Cited by: 5; All Open Access, Gold Open Access, Green Open Access |
Uncontrolled Keywords: | aromatase inhibitor; high density lipoprotein cholesterol; hormone receptor; low density lipoprotein cholesterol; tamoxifen; adult; aged; Article; body mass; cancer survival; chemotherapy; controlled study; diabetes mellitus; dyslipidemia; fatty liver; female; follow up; human; human epidermal growth factor receptor 2 positive breast cancer; hyperglycemia; hypertension; hypertriglyceridemia; major clinical study; male; mammography; metabolic syndrome X; middle aged; osteoporosis; overall survival; risk factor; survival analysis; thorax radiography; thromboembolism; tumor volume |
Subjects: | R Medicine > RB Biomedical Sciences |
Divisions: | Faculty of Medicine, Public Health and Nursing > Biomedical Sciences |
Depositing User: | Sri JUNANDI |
Date Deposited: | 27 Sep 2024 01:00 |
Last Modified: | 27 Sep 2024 01:00 |
URI: | https://ir.lib.ugm.ac.id/id/eprint/4594 |